Chronic Hepatitis B Virus Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

May 11 19:40 2023
Chronic Hepatitis B Virus Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 55+ pipeline drugs in the Chronic Hepatitis B Virus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Chronic Hepatitis B Virus Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chronic Hepatitis B Virus Market. 

The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chronic Hepatitis B Virus Pipeline Analysis

Chronic Hepatitis B Virus Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Chronic Hepatitis B Virus and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chronic Hepatitis B Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Chronic Hepatitis B Virus Therapeutic Segment @

Chronic Hepatitis B Virus Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Chronic Hepatitis B Virus Infection. Currently, Ligand Pharmaceuticals is leading the therapeutics market with its Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage of clinical development.

The Leading Players in the Chronic Hepatitis B Virus Therapeutics Market Include:

Antios Therapeutics, Arbutus Biopharma, Ascentage Pharma, Ascletis Pharmaceuticals, Assembly Biosciences, Brii Biosciences, Chong Kun Dang Pharmaceutical, Dong-A ST Co, Enanta Pharmaceuticals, Enyo Pharma, Gilead Sciences, GlaxoSmithKline, Golden Biotechnology, Guangzhou Lupeng Pharmaceutical, Henlix, Janssen Sciences, Jiangsu HengRui Medicine, Nucorion Pharmaceuticals, PharmaEssentia, Qilu Pharmaceutical, Romark Laboratories, Shanghai HEP Pharmaceutical, Sunshine Lake Pharma, Suzhou Ribo Life Science, Tasly Tianjin Biopharmaceutical, Vaccitech limited, Vaxine Pty Ltd, Vedanta Biosciences, VenatoRx Pharmaceuticals, Vir Biotechnology, Zhejiang Palo Alto Pharmaceuticals, Zhimeng Biopharm, and others.

Chronic Hepatitis B Virus Infection Emerging and Marketed Drugs Covered in the Report Include:

  • AB-729 (GaINAc-RNAi): Arbutus Biopharma

  • GSK3389404 (IONIS-HBV-LRX): GlaxoSmithKline /Ionis Pharmaceuticals

  • JNJ-73763989 and/or JNJ-56136379: Janssen/Arrowhead Pharmaceuticals

  • Pradefovir: Ligand Pharmaceuticals

  • REP 2165 + REP 2139: Replicor

  • RG6346: Dicerna Pharmaceuticals

  • RG7854/RG7907/RG6346: Roche

  • Selgantolimod (GS-9688): Gilead Sciences

  • Vebicorvir (VBR, or ABI-H0731): Assembly Biosciences

  • VIR-2218 ± PEG-IFN-⍺: Vir Biotechnology

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Chronic Hepatitis B Virus Current Treatment Patterns

4. Chronic Hepatitis B Virus – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Hepatitis B Virus Late Stage Products (Phase-III)

7. Chronic Hepatitis B Virus Mid-Stage Products (Phase-II)

8. Chronic Hepatitis B Virus Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Hepatitis B Virus Discontinued Products

13. Chronic Hepatitis B Virus Product Profiles

14. Key Companies in the Chronic Hepatitis B Virus Market

15. Key Products in the Chronic Hepatitis B Virus Therapeutics Segment

16. Dormant and Discontinued Products

17. Chronic Hepatitis B Virus Unmet Needs

18. Chronic Hepatitis B Virus Future Perspectives

19. Chronic Hepatitis B Virus Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States